What are the psychological and physical effects of using 1,4‑butanediol in a person with attention‑deficit/hyperactivity disorder (ADHD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Effects of 1,4-Butanediol Use in Persons with ADHD

Do not use 1,4-butanediol if you have ADHD—this industrial solvent is a dangerous substance of abuse that converts to gamma-hydroxybutyrate (GHB) in the body and carries serious risks of death, coma, respiratory depression, and addiction, with no therapeutic benefit for ADHD.

What 1,4-Butanediol Actually Is

1,4-butanediol (1,4-BD) is not a medication—it's an industrial solvent that has been illicitly marketed as a dietary supplement and recreational drug 1. When you ingest it, your body rapidly converts it to GHB, a potent central nervous system depressant 2. This is completely different from the FDA-approved ADHD medications (stimulants like methylphenidate/amphetamines or non-stimulants like atomoxetine, guanfacine, clonidine) 3.

The FDA drug label you might encounter for "1,4-butanediol" actually refers to busulfan (a chemotherapy drug for leukemia), which has the chemical name "1,4-butanediol dimethanesulfonate"—this is a completely different compound and not what people abuse recreationally 4.

Psychological Effects in Someone with ADHD

Acute Intoxication Effects:

  • Altered consciousness: Fluctuating between agitation/combativeness and sedation 5
  • Euphoria and relaxation at lower doses, progressing to deep sedation and coma at higher doses 6
  • Respiratory depression that can be fatal 5
  • Vomiting, loss of bladder/bowel control 5
  • Effects begin within 24 minutes of ingestion and last several hours 2

Addiction and Withdrawal:

  • High addiction potential with severe withdrawal symptoms 1
  • Withdrawal can include delirium 1
  • One patient in a case series presented twice with toxic effects and developed withdrawal symptoms 5

No Therapeutic Benefit for ADHD:

There is zero evidence that 1,4-BD helps ADHD symptoms. In fact, the limited research on other substances of abuse in ADHD shows:

  • Cannabis users with ADHD show worse cognitive performance on objective testing despite subjective feelings of improvement 7
  • The psychoactive effects of 1,4-BD (sedation, euphoria) are opposite to what ADHD requires—which is enhanced attention and executive function 3, 8

Physical Effects

Immediate Physical Dangers:

  • Respiratory depression leading to death—two deaths occurred at doses of 5.4-20 grams 5
  • Cardiovascular effects: Transient increases in blood pressure, decreased oxygen saturation 2
  • Loss of physical control: Urinary and fecal incontinence 5
  • Doses as low as 1 gram have caused toxic effects 5

Pharmacology:

  • Rapidly absorbed (peak levels at 24 minutes) 2
  • Converted extensively to GHB (peak GHB levels at 39 minutes) 2
  • Individual metabolism varies significantly—some people metabolize it much more slowly, potentially due to genetic variants in alcohol dehydrogenase enzymes, leading to prolonged toxic effects 2

Critical Context for ADHD Patients

People with ADHD are at higher risk for substance use disorders 9. The evidence shows:

  • ADHD increases risk for cannabis use and other substance misuse 9
  • Substance use in adolescents/young adults with ADHD causes additional neurocognitive deficits, including worsened executive function, memory, and processing speed 9
  • Proper ADHD treatment involves FDA-approved medications (stimulants or non-stimulants) combined with behavioral interventions 3, 8

The Bottom Line

1,4-butanediol is a toxic industrial chemical with documented fatalities, not a treatment option. If you or someone with ADHD is considering this substance:

  • Immediate risk: Coma, respiratory arrest, death—even at relatively low doses
  • No benefit: Zero evidence for ADHD symptom improvement; likely worsens cognitive function
  • High addiction risk: Severe withdrawal and dependence potential
  • Proper treatment exists: FDA-approved stimulants (methylphenidate, amphetamines) and non-stimulants (atomoxetine, guanfacine, clonidine) are safe, effective, and monitored 3, 8

If someone with ADHD is using 1,4-BD, this represents a medical emergency and substance use disorder requiring immediate intervention, not a treatment strategy.

Related Questions

In a 13‑year‑old with attention‑deficit/hyperactivity disorder, should treatment begin with a stimulant or a non‑stimulant, and what are the recommended dosing and monitoring considerations?
In a 14‑year‑old female with ADHD whose main symptom is difficulty staying on task, weighing 97 lb (≈44 kg) and previously treated with methylphenidate, what is the appropriate starting dose of extended‑release methylphenidate—18 mg or 27 mg?
In a 15-year-old male with ADHD and a mood disorder who is currently taking escitalopram 10 mg daily and dexmethylphenidate extended-release 20 mg daily, and who has been off trazodone for two months after previously using 150 mg at bedtime, can trazodone be restarted at 50 mg?
What is the appropriate workup and initial management for a 20-year-old male with ADHD (off medication) who has persistent hypertension for one week, is physically fit, non‑overweight, and experiencing academic stress with a family history of breast cancer?
What is an appropriate treatment plan for mild anxiety in a 12-year-old patient with ADHD who is currently using transdermal methylphenidate (Daytrana)?
What is the recommended norepinephrine (Norad) infusion dosage and titration protocol for an adult patient with hypotension or shock, including considerations for older patients or those with known cardiac disease?
How is acute disseminated encephalomyelitis (ADEM) diagnosed?
For a patient with invasive ductal carcinoma of the breast, stage III B and progressive disease, what other chemotherapy regimens and their dosing can be used?
What dose and duration of vitamin E (natural d‑alpha‑tocopherol) therapy are recommended for a patient with grade 1 diffuse fatty infiltration of the liver?
What is the appropriate management of disseminated intravascular coagulation (DIC) with thrombocytopenia and hypoalbuminemia?
How should I correct a serum magnesium of 1.36 mg/dL—can I give 200 mg of elemental magnesium and how often should it be administered?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.